Digitalizing the TIM-1 Model Using Computational Approaches─Part Two: Digital TIM-1 Model in GastroPlus

Digitalizing the TIM-1 Model Using Computational Approaches─Part Two: Digital TIM-1 Model in GastroPlus

Publication: Mol Pharm
Software: GastroPlus®

A TIM-1 model is an in vitro gastrointestinal (GI) simulator considering crucial physiological parameters that will affect the in vivo drug release process.

Ionization Prediction Summit Webinar Series: Session 1 Fundamentals of Ionization

Ionization Prediction Summit Webinar Series: Session 1 Fundamentals of Ionization

Software: ADMET Predictor®
Division: PBPK

In the Ionization Prediction Summit webinar series, leading industry experts will explain ionization, how ionization modeling works, how ionization models are influenced by the large amounts of industrial data...

Mechanistic modeling of intramuscular administration of long-acting injectable suspensions accounting for fibrosis at the depot site

Mechanistic modeling of intramuscular administration of long-acting injectable suspensions accounting for fibrosis at the depot site

Conference: AAPS
Software: GastroPlus®
Division: PBPK

Antipsychotic drugs formulated as long-acting injectables (LAIs) significantly improve patient compliance compared to regimens that require daily oral administration.

Physiologically Based Pharmacokinetic (PBPK) Modeling of Fexofenadine and Assessment of Transporter DDIs of Fexofenadine with P-gp inducers and inhibitors

Physiologically Based Pharmacokinetic (PBPK) Modeling of Fexofenadine and Assessment of Transporter DDIs of Fexofenadine with P-gp inducers and inhibitors

Conference: AAPS
Software: GastroPlus®
Division: PBPK

Fexofenadine (FEX), a H1-receptor antagonist used in the treatment of allergic rhinitis and chronic idiopathic urticaria, undergoes minimal metabolism and transporters play a major role in its absorption and disposition.

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

Publication: Pharmaceutics
Software: GastroPlus®
Division: PBPK

Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug...

Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs

Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs

Authors: Lee DY, Kang HE
Publication: Xenobiotica

The pharmacokinetics of a new 5-hydroxytryptamine receptor 4 agonist, DA-6886, intended for the treatment of constipation-predominant irritable bowel syndrome...

Population Pharmacokinetics of Molnupiravir in Adults With COVID-19: Lack of Clinically Important Exposure Variation Across Individuals

Population Pharmacokinetics of Molnupiravir in Adults With COVID-19: Lack of Clinically Important Exposure Variation Across Individuals

Publication: CPT Pharmacometrics Syst Pharmacol

Effective antiviral treatments for coronavirus disease 2019 (COVID-19) are needed to reduce the morbidity and mortality associated with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, particularly...

From Target Identification to Novel Lead: How Multi-omics Analysis and AI-driven Drug Design Can Accelerate Early Drug Discovery

From Target Identification to Novel Lead: How Multi-omics Analysis and AI-driven Drug Design Can Accelerate Early Drug Discovery

Software: ADMET Predictor®
Division: PBPK

One of the key areas for optimization in the drug development process is the discovery stage. Traditional methods are time-consuming and often produce leads that ultimately fail.